CMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target

Stock News06-22

CMSC International has released a research report initiating coverage on RIBOLIFE-B (06938) with an "Add" rating and a target price of HK$105. The firm is optimistic about the company's core asset, RBD4059, which is positioned as the world's first small interfering RNA (siRNA) anticoagulant targeting coagulation factor XI. This product has the potential to become a new generation of long-acting anticoagulation therapy.

The report highlights that the global anticoagulant market is projected to reach a future capacity of up to $60 billion. Bayer's Asundexian, the world's first small molecule targeting coagulation factor XIa, has already submitted a marketing application to the US FDA in May and is expected to launch by year-end. This development is anticipated to reshape the global competitive landscape for anticoagulants.

CMSC International currently forecasts that RIBOLIFE-B will generate revenues of approximately RMB 442 million, RMB 115 million, and RMB 147 million for the years 2026, 2027, and 2028, respectively. The firm also predicts the company will record annual net losses of around RMB 288 million, RMB 38 million, and RMB 335 million for the same periods.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1177506769?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-22 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1177506769","market":"us","top_or_hot":-1,"title":"CMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target","media":"Stock News","content":"<p>CMSC International has released a research report initiating coverage on <b>RIBOLIFE-B</b> (<b>06938</b>) with an \"Add\" rating and a target price of HK$105. The firm is optimistic about the company's core asset, RBD4059, which is positioned as the world's first small interfering RNA (siRNA) anticoagulant targeting coagulation factor XI. This product has the potential to become a new generation of long-acting anticoagulation therapy.<br><br>The report highlights that the global anticoagulant market is projected to reach a future capacity of up to $60 billion. Bayer's Asundexian, the world's first small molecule targeting coagulation factor XIa, has already submitted a marketing application to the US FDA in May and is expected to launch by year-end. This development is anticipated to reshape the global competitive landscape for anticoagulants.<br><br>CMSC International currently forecasts that <b>RIBOLIFE-B</b> will generate revenues of approximately RMB 442 million, RMB 115 million, and RMB 147 million for the years 2026, 2027, and 2028, respectively. The firm also predicts the company will record annual net losses of around RMB 288 million, RMB 38 million, and RMB 335 million for the same periods.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCMSC Initiates Coverage on RIBOLIFE-B with 'Add' Rating and HK$105 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-06-22 15:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CMSC International has released a research report initiating coverage on <b>RIBOLIFE-B</b> (<b>06938</b>) with an \"Add\" rating and a target price of HK$105. The firm is optimistic about the company's core asset, RBD4059, which is positioned as the world's first small interfering RNA (siRNA) anticoagulant targeting coagulation factor XI. This product has the potential to become a new generation of long-acting anticoagulation therapy.<br><br>The report highlights that the global anticoagulant market is projected to reach a future capacity of up to $60 billion. Bayer's Asundexian, the world's first small molecule targeting coagulation factor XIa, has already submitted a marketing application to the US FDA in May and is expected to launch by year-end. This development is anticipated to reshape the global competitive landscape for anticoagulants.<br><br>CMSC International currently forecasts that <b>RIBOLIFE-B</b> will generate revenues of approximately RMB 442 million, RMB 115 million, and RMB 147 million for the years 2026, 2027, and 2028, respectively. The firm also predicts the company will record annual net losses of around RMB 288 million, RMB 38 million, and RMB 335 million for the same periods.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06938","symbol_name":"瑞博生物-B","start_time":0,"source_url":"","article_id":"1177506769","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1177506769","pubTimestamp":1782112702,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CMSC International has released a research report initiating coverage on RIBOLIFE-B (06938) with an \"Add\" rating and a target price of HK$105. The firm is optimistic about the company's core asset,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06938":"瑞博生物-B","EWH":"香港ETF-iShares MSCI","BK1564":"中资券商股","06099":"招商证券","BK1161":"生物科技","BK1147":"投资银行业与经纪业"},"translate_title":"CMSC首次对RIBOLIFE-B给予“增持”评级和105港元目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06938":1,"06099":1,"EWH":1},"content_text":"CMSC International has released a research report initiating coverage on RIBOLIFE-B (06938) with an \"Add\" rating and a target price of HK$105. The firm is optimistic about the company's core asset, RBD4059, which is positioned as the world's first small interfering RNA (siRNA) anticoagulant targeting coagulation factor XI. This product has the potential to become a new generation of long-acting anticoagulation therapy.The report highlights that the global anticoagulant market is projected to reach a future capacity of up to $60 billion. Bayer's Asundexian, the world's first small molecule targeting coagulation factor XIa, has already submitted a marketing application to the US FDA in May and is expected to launch by year-end. This development is anticipated to reshape the global competitive landscape for anticoagulants.CMSC International currently forecasts that RIBOLIFE-B will generate revenues of approximately RMB 442 million, RMB 115 million, and RMB 147 million for the years 2026, 2027, and 2028, respectively. The firm also predicts the company will record annual net losses of around RMB 288 million, RMB 38 million, and RMB 335 million for the same periods.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1177506769","isCrawlerRequest":true}